Gynecomastia Treatment Market is predicted to reach USD 1.60 billion at a CAGR of 7.80% during the forecast period 2023-2032

Market Research Future (MRFR) has published on the “Global Gynecomastia Treatment Market”.

The Gynecomastia Treatment Market is estimated to register a CAGR of 7.80% during the forecast period of 2023 to 2032.

MRFR recognizes the following companies as the key players in the global Gynecomastia Treatment Market— Allergan plc, Pfizer Inc., Johnson & Johnson, Merck & Co., Inc., Novartis International AG, Eli Lilly and Company, AbbVie Inc., Ipsen Pharma, Endo Pharmaceuticals Inc. and Sandoz International GmbH.

Gynecomastia Treatment Market Highlights

The global Gynecomastia Treatment Market is accounted to register a CAGR of 7.80% during the forecast period and is estimated to reach USD 1.60 billion by 2032.

The gynecomastia treatment market is growing due to a heightened emphasis on aesthetic appearance, increasing awareness of gynecomastia, and advancements in cosmetic surgery techniques. The rising prevalence of hormonal imbalances and obesity, which contribute to gynecomastia, fuels the demand for treatment options. Moreover, a growing acceptance of cosmetic procedures among men and the desire for a more contoured chest drive the market's expansion. Innovations in minimally invasive treatments and the accessibility of various surgical options further contribute to market growth.

Segment Analysis

The global Gynecomastia Treatment Market has been segmented based type and application.

On the basis of type, the market is segmented into Drugs, Surgical Treatment. The drugs segment captured the largest market share in the Gynecomastia Treatment market in 2022, due to their non-invasive nature and efficacy in addressing hormonal imbalances.

Based on application, the global Gynecomastia Treatment Market has been segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. The Hospital pharmacies segment captured the largest market share in the Gynecomastia Treatment market in 2022, due to their role as integral components of healthcare institutions.

Browse In-depth Market Details [Table of Content, List of Figures, List of Tables] of Gynecomastia Treatment Market Research Report

Regional Analysis

The global Gynecomastia Treatment Market, based on region, has been divided into the North America, Europe, Asia-Pacific, and Rest of the World. North America consists of US and Canada. The Europe Gynecomastia Treatment Market comprises of Germany, France, the UK, Italy, Spain, and the rest of Europe. The Gynecomastia Treatment Market in Asia-Pacific has been segmented into China, India, Japan, Australia, South Korea, and the rest of Asia-Pacific. The Rest of the World Gynecomastia Treatment Market comprises of Middle East, Africa, and Latin America.

The largest market share for Nuclear Fuels was maintained by the North American regional sector. North America has captured the largest market share in the Gynecomastia Treatment market due to factors such as advanced healthcare infrastructure, high awareness levels, and a growing acceptance of aesthetic procedures. The region's robust healthcare system, coupled with a significant emphasis on physical appearance and wellness, drives the demand for gynecomastia treatments. Additionally, the presence of key market players, well-established medical facilities, and the cultural openness to cosmetic interventions contribute to North America's dominance in the Gynecomastia Treatment market.

Moreover, the Europe market has been persistently growing over the forecast period. Europe has secured the second-largest market share in the Gynecomastia Treatment market owing to its advanced healthcare systems, cultural acceptance of cosmetic procedures, and a proactive approach to men's health. The region's well-established medical infrastructure and increasing awareness of gynecomastia treatment options contribute to market growth. Additionally, regulatory support and a higher prevalence of aesthetic concerns among men further solidify Europe's position as a key player in the Gynecomastia Treatment market, capturing the second-largest market share.

The Asia Pacific region is experiencing the highest Compound Annual Growth Rate (CAGR) in the Gynecomastia Treatment market due to a rising awareness of aesthetic procedures, evolving healthcare infrastructure, and a growing middle-class population. Increased disposable incomes and changing beauty standards contribute to the demand for gynecomastia treatments. Moreover, the adoption of Western beauty ideals and a surge in medical tourism further drive market growth in the Asia Pacific region. These factors collectively position the region at the forefront of the Gynecomastia Treatment market with the highest CAGR.

Furthermore, the rest of the world's Gynecomastia Treatment Market is divided into the Middle East, Africa, and Latin America. The rest of the world is witnessing growth in the Gynecomastia Treatment market due to increasing awareness of cosmetic procedures, rising disposable income, and changing cultural perceptions of aesthetic interventions. As the acceptance of gynecomastia treatments grows, a rising demand for cosmetic enhancements contributes to market expansion in these regions.

Key Findings of the Study

• The global Gynecomastia Treatment Market is expected to reach USD 1.60 billion by 2032, at a CAGR of 7.80% during the forecast period.


• The Asia Pacific region is the fastest-growing in the Gynecomastia Treatment market due to a growing middle-class population, rising awareness of cosmetic procedures, and evolving beauty standards. Increasing acceptance of aesthetic interventions and advancements in healthcare infrastructure contribute to the rapid market expansion.


• Based on type, the Drugs segment was attributed to holding the largest market in 2022, with an approximate market share of 61–66%.


• Allergan plc, Pfizer Inc., Johnson & Johnson, Merck & Co., Inc., Novartis International AG, Eli Lilly and Company, AbbVie Inc., Ipsen Pharma, Endo Pharmaceuticals Inc. and Sandoz International GmbH.